NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. QCOM
2. CBRS
3. FDX
4. USO
5. SPY
6. MU
7. KBH
8. HTZ
9. HON
10. JPM

Go back to NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
(NASDAQ: NRSN) Delayed: 0.76 -0.01 (1.3%)
Previous Close $0.77    52 Week High $ 
Open $0.77    52 Week Low $ 
Day High $0.78    P/E N/A 
Day Low $0.75    EPS $ 
Volume 57,822